Medtronic Plc ($MDT) has seen varied recent investor activity, with Illinois Municipal Retirement Fund and Wealthfront Advisers LLC increasing their shareholdings, while Rhumbline Advisers and Madison Asset Management have divested. Several investments firms such as Principal Financial Group and Jones Financial Companies significantly expanded their stake. In terms of financial results, there are anticipations about the third quarter fiscal year 2026 results. On the product front, Medtronic obtained FDA clearance for its Stealth AXiS™ surgical system for spine surgery, marking another achievement for the company. A survey on RDN procedure volumes also creates optimism for Medtronic’s future. In addition, Medtronic declared its intent to acquire CathWorks to bolster its portfolio. However, the antitrust verdict targeting hospital contracts could influence the bull case for Medtronic. Posing a possible concern, the company saw bearish options activity despite the long-term growth outlook. Price target and upgrade announcements by Needham and Barclays attracted attention. Jim Cramer projected better than expected numbers for Medtronic, emphasizing the CEO as a significant asset. The firm proceeded to close a public offering of €1.5 billion of senior notes.
Medtronic Plc MDT News Analytics from Tue, 02 Sep 2025 07:00:00 GMT to Fri, 13 Feb 2026 19:18:45 GMT -
Rating 2
- Innovation 1
- Information 8
- Rumor -2
